No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Optimized pharmacokinetic modeling for the detection of perfusion differences in skeletal muscle with DCE-MRI: Effect of contrast agent size
3.S. H. Schirmer, F. C. van Nooijen, J. J. Piek, and N. van Royen, “Stimulation of collateral artery growth: Travelling further down the road to clinical application,” Heart 95(3), 191–197 (2009).
5.Q. G. de Lussanet et al., “Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer,” Int. J. Radiat. Oncol., Biol., Phys. 63(5), 1309–1315 (2005).
7.A. R. Padhani, “Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions,” J. Magn. Reson Imaging 16(4), 407–422 (2002).
8.M. A. Zahra, K. G. Hollingsworth, E. Sala, D. J. Lomas, and L. T. Tan, “Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy,” Lancet Oncol. 8(1), 63–74 (2007).
9.N. Al-Saadi et al., “Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance,” Circulation 101(12), 1379–1383 (2000).
10.N. Wilke et al., “Myocardial perfusion reserve: Assessment with multisection, quantitative, first-pass MR imaging,” Radiology 204(2), 373–384 (1997).
11.Q. G. de Lussanet et al., “Dynamic contrast-enhanced MRI of muscle perfusion combined with MR angiography of collateral artery growth in a femoral artery ligation model,” NMR Biomed. 20, 717–725 (2007).
12.A. Z. Faranesh, D. L. Kraitchman, and E. R. McVeigh, “Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent,” Magn. Reson. Med. 55(5), 1114–1123 (2006).
13.S. M. Galbraith et al., “Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis,” NMR Biomed. 15(2), 132–142 (2002).
14.R. B. Thompson et al., “Measurement of skeletal muscle perfusion during postischemic reactive hyperemia using contrast-enhanced MRI with a step-input function,” Magn. Reson. Med. 54(2), 289–298 (2005).
15.T. A. Goldstein, M. Jerosch-Herold, B. Misselwitz, H. Zhang, R. J. Gropler, and J. Zheng, “Fast mapping of myocardial blood flow with MR first-pass perfusion imaging,” Magn. Reson. Med. 59(6), 1394–1400 (2008).
16.Y. Luo et al., “Evaluation of tissue perfusion in a rat model of hind-limb muscle ischemia using dynamic contrast-enhanced magnetic resonance imaging,” J. Magn. Reson Imaging 16(3), 277–283 (2002).
17.H. J. Aerts, N. A. van Riel, and W. H. Backes, “System identification theory in pharmacokinetic modeling of dynamic contrast-enhanced MRI: Influence of contrast injection,” Magn. Reson. Med. 59(5), 1111–1119 (2008).
19.R. G. Lopata, W. H. Backes, P. P. van den Bosch, and N. A. van Riel, “On the identifiability of pharmacokinetic parameters in dynamic contrast-enhanced imaging,” Magn. Reson. Med. 58(2), 425–429 (2007).
20.B. Misselwitz, H. Schmitt-Willich, W. Ebert, T. Frenzel, and H. J. Weinmann, “Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent,” MAGMA (N.Y.) 12(2–3), 128–134 (2001).
21.K. Jaspers et al., “Reliability of pharmacokinetic parameters: Small vs. medium-sized contrast agents,” Magn. Reson. Med. 62(3), 779–787 (2009).
22.S. Walker-Samuel, M. O. Leach, and D. J. Collins, “Evaluation of response to treatment using DCE-MRI: The relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis,” Phys. Med. Biol. 51(14), 3593–3602 (2006).
25.C. S. Patlak, R. G. Blasberg, and J. D. Fenstermacher, “Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data,” J. Cereb. Blood Flow Metab. 3(1), 1–7 (1983).
26.H. Daldrup et al., “Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media,” AJR, Am. J. Roentgenol. 171(4), 941–949 (1998).
27.K. Turetschek et al., “Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights,” J. Magn. Reson Imaging 20(1), 138–144 (2004).
28.H. L. Cheng, C. Wallis, Z. Shou, and W. A. Farhat, “Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights,” J. Magn. Reson Imaging 25(1), 137–145 (2007).
29.S. B. Donaldson et al., “A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: Application in carcinoma of the cervix,” Magn. Reson. Med. 63(3), 691–700 (2010).
30.D. L. Buckley, “Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI,” Magn. Reson. Med. 47(3), 601–606 (2002).
31.I. E. Hoefer, N. van Royen, I. R. Buschmann, J. J. Piek, and W. Schaper, “Time course of arteriogenesis following femoral artery occlusion in the rabbit,” Cardiovasc. Res. 49(3), 609–617 (2001).
36.E. M. Haacke, R. W. Brown, M. R. Thompson, and R. Venkatesan, Magnetic Resonance Imaging: Physical Principles and Sequence Design (Wiley, New York, 1999).
37.M. Rohrer, H. Bauer, J. Mintorovitch, M. Requardt, and H. J. Weinmann, “Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths,” Invest. Radiol. 40(11), 715–724 (2005).
38.J. R. Ewing et al., “Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor,” J. Cereb. Blood Flow Metab. 26(3), 310–320 (2006).
39.D. Bates and D. Watts, Nonlinear Regression Analysis and Its Applications (Wiley, New York, 1988).
40.F. Bourasset, A. Dencausse, P. Bourrinet, M. Ducret, and C. Corot, “Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model,” MAGMA (N.Y.) 12(2–3), 82–87 (2001).
42.H. E. Daldrup-Link et al., “Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging,” Acad. Radiol. 7(11), 934–944 (2000).
46.L. Ludemann, B. Schmitt, P. Podrabsky, B. Schnackenburg, J. Bock, and M. Gutberlet, “Usage of the T1 effect of an iron oxide contrast agent in an animal model to quantify myocardial blood flow by MRI,” Eur. J. Radiol. 62(2), 247–256 (2007).
47.K. Turetschek et al., “Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology,” Magn. Reson. Med. 45(5), 880–886 (2001).
48.A. Jacquier et al., “MR imaging assessment of the kinetics of P846, a new gadolinium-based MR contrast medium, in ischemically injured myocardium,” Contrast Media Mol. Imaging 3(3), 112–119 (2008).
49.R. B. Lauffer et al., “MS-325: Albumin-targeted contrast agent for MR angiography,” Radiology 207(2), 529–538 (1998).
50.C. Corot, X. Violas, P. Robert, G. Gagneur, and M. Port, “Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol,” Invest. Radiol. 38(6), 311–319 (2003).
51.K. Turetschek et al., “MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology,” J. Magn. Reson Imaging 14(3), 237–242 (2001).
52.B. L. Gerber et al., “Single-vessel coronary artery stenosis: Myocardial perfusion imaging with Gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine,” Radiology 225(1), 104–112 (2002).
53.K. M. Choi, R. J. Kim, G. Gubernikoff, J. D. Vargas, M. Parker, and R. M. Judd, “Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function,” Circulation 104(10), 1101–1107 (2001).
Article metrics loading...
Full text loading...
Most read this month